Recombinant Human TP53 protein, GST-tagged
Cat.No. : | TP53-15H |
Product Overview : | Recombinant Human TP53 fused with GST tag at N-terminal was expressed in E. coli. |
Unit | |
Price | |
Qty |
- Specification
- Gene Information
- Related Products
Description : | p53 is a key regulator of cell growth and acts as a tumor suppressor gene. Wild-type p53 gene can suppress transformation of rat embryo fibroblasts in cell culture by other oncogenes such as the adenovirus E1A and Ras. DNA tumor viruses such as SV40 large T antigen and the adenovirus E1A plus E1B-55Kd proteins bind to p53 and inactivate its tumor suppressor activities leading to cellular transformation. Mutational inactivation of the p53 gene is detected in more than 50% of human cancers. Mutation of p53 renders cancer cells more resistant to current cancer therapies due to lack of p53-mediated apoptosis. |
Source : | E. coli |
Species : | Human |
Tag : | GST |
Form : | 50mM Tris-HCl, pH 7.5, 150mM NaCl, 0.25mM DTT, 0.1mM EGTA, 0.1mM EDTA, 0.1mM PMSF, 25% glycerol. |
Molecular Mass : | ~79 kDa |
Purity : | Greater than 75.0% |
Applications : | Kinase Assay, Western Blot |
Stability : | 1 year at -70 centigrade from the date of shipment |
Storage : | Store product at –70 centigrade. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. |
Concentration : | 0.2μg/μl |
Publication : |
c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis (2020)
|
Gene Name : | TP53 tumor protein p53 [ Homo sapiens ] |
Official Symbol : | TP53 |
Synonyms : | TP53; tumor protein p53; cellular tumor antigen p53; LFS1; Li Fraumeni syndrome; p53; antigen NY-CO-13; mutant p53 protein; phosphoprotein p53; p53 tumor suppressor; truncated p53 protein; tumor suppressor TP53; transformation-related protein 53; P53; TRP53; FLJ92943; |
Gene ID : | 7157 |
mRNA Refseq : | NM_000546 |
Protein Refseq : | NP_000537 |
MIM : | 191170 |
UniProt ID : | P04637 |
Chromosome Location : | 17p13.1 |
Pathway : | Activation of BH3-only proteins, organism-specific biosystem; Activation of NOXA and translocation to mitochondria, organism-specific biosystem; Activation of PUMA and translocation to mitochondria, organism-specific biosystem; Amyotrophic lateral sclerosis (ALS), organism-specific biosystem; Amyotrophic lateral sclerosis (ALS), conserved biosystem; Androgen Receptor Signaling Pathway, organism-specific biosystem; Apoptosis, organism-specific biosystem; |
Products Types
◆ Recombinant Protein | ||
TP53-2772H | Recombinant Human TP53 Protein, His-tagged | +Inquiry |
TP53-2235H | Recombinant Human TP53 Protein, His (Fc)-Avi-tagged | +Inquiry |
TP53-5887R | Recombinant Rat TP53 Protein, His (Fc)-Avi-tagged | +Inquiry |
TP53-787C | Recombinant Cynomolgus Monkey TP53 Protein, His (Fc)-Avi-tagged | +Inquiry |
TP53-4893H | Recombinant Human TP53 (Y220C) Protein, Myc/DDK-tagged | +Inquiry |
◆ Lysates | ||
TP53-860HCL | Recombinant Human TP53 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (5)
Ask a questionYes, identifying TP53 mutations in families with a history of early-onset cancers can help identify individuals at high risk for cancer and guide screening and prevention strategies.
TP53 mutations are highly diverse, making it challenging to develop a one-size-fits-all therapy. Additionally, the p53 pathway is complex, and disrupting it can have unintended consequences.
Yes, TP53 mutation status can be a criterion for eligibility in specific clinical trials, especially those testing experimental treatments that may target the p53 pathway.
TP53 status can influence treatment decisions. For example, patients with TP53 mutations may require more aggressive treatment approaches or different chemotherapy regimens.
Currently, there are no specific targeted therapies approved solely for TP53-mutated cancers. However, research is ongoing to develop drugs that target the altered p53 pathway.
Customer Reviews (3)
Write a reviewBy actively engaging with researchers and understanding their needs, manufacturers can contribute significantly to the success and impact of research involving the TP53 protein.
This flexibility allows for tailored approaches and provides researchers with more options to study specific aspects of TP53 biology or its interactions with other molecules.
Manufacturers can provide comprehensive product information, including data on the functionality, stability, and handling of TP53 protein.
Ask a Question for All TP53 Products
Required fields are marked with *
My Review for All TP53 Products
Required fields are marked with *
Inquiry Basket